SCHEDULE: Valion Bio Amendment 6: 3i LP Increases Stake

Valion Bio, Inc. files Amendment No. 6 to Schedule 13D, detailing a significant transaction by 3i, LP involving preferred stock, warrants, and a convertible note.

Summary

• This filing is an amendment (Amendment No. 6) to a Schedule 13D for Valion Bio, Inc., concerning common stock.
• The amendment details transactions by reporting persons including 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow.
• On August 31, 2026, Valion Bio and 3i, LP entered into a letter agreement where 3i, LP received Series B Preferred Stock, warrants, and Series C Preferred Stock.
• The aggregate purchase price for these securities was $7,737,000, with $6,137,000 retained by 3i, LP for overdue cash true-up payments, $100,000 for legal counsel fees, and $1,500,000 paid to the Issuer.
• As of August 24, 2026, 3i, LP beneficially owns 133,005 shares of common stock, representing 9.9% of the class, based on 1,285,626 shares outstanding.
• This ownership includes directly held shares and shares issuable upon exercise of warrants and conversion of convertible notes and preferred stock, all subject to a 9.99% beneficial ownership limitation (Blocker).
• A transaction on September 2, 2026, involved 3i, LP purchasing 3,248 shares of common stock at $2.9155 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the ongoing nature of capital infusions and potential dilution, despite the company's efforts to manage its financial position.

Positives

• 3i, LP continues to invest in Valion Bio, Inc., indicating confidence in the company's potential.
• The company received $1.5 million in immediate funds from the August 31, 2026 transaction.
• The ownership stake of 9.9% by 3i, LP is significant and suggests a substantial investor relationship.

Negatives

• A large portion of the $7.737 million transaction was retained by 3i, LP for overdue payments and legal fees, rather than being directly injected as new capital for operations.
• The beneficial ownership is subject to a 9.99% 'Blocker' provision, which limits the ability to convert or exercise, potentially capping upside for 3i, LP.
• The filing indicates ongoing financial arrangements and potential dilution through convertible instruments and warrants.

Risks

• Potential for significant dilution to existing shareholders if warrants are exercised or convertible notes/preferred stock are converted, subject to the 9.99% ownership limitation.
• The need for 'cash true-up payments' suggests potential ongoing financial strain or complex financial arrangements.
• The reliance on specific investors like 3i, LP for capital can create dependency and influence.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Valion Bio, Inc. However, the ongoing transactions involving convertible instruments and warrants suggest potential future capital raises or dilutive events, subject to the 9.99% ownership limitation.

Management Comments

• No direct management comments are included in this amendment; it primarily details transactions and ownership.
• The signature block indicates Maier J. Tarlow acting as manager for 3i Management LLC (general partner of 3i, LP and manager of Tumim Stone Capital, LLC) and as an individual reporting person.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy in the biotech/pharma sector where early-stage or development-stage companies often rely on structured financing involving convertible notes and warrants, alongside preferred stock issuances, to fund operations and R&D. The 'Blocker' provision is a standard mechanism to manage beneficial ownership thresholds, particularly for investors aiming to avoid triggering certain regulatory requirements or ownership caps.

Related Party Transactions

• The transactions detailed in the filing involve 3i, LP, 3i Management LLC, Tumim Stone Capital, LLC, and Maier J. Tarlow, who appear to be related parties or acting in concert, as indicated by their shared reporting status and Maier J. Tarlow's roles across these entities.

Stakeholder Impact

• Shareholders: Potential for dilution due to the conversion of preferred stock and exercise of warrants. The 9.9% ownership by 3i, LP also signifies a significant stakeholder influence.
• Creditors: The 'overdue cash true-up payments' suggest potential strain on financial obligations, which could impact creditors.
• Management/Board: The significant stake and ongoing financial arrangements with 3i, LP may influence strategic decisions and board composition discussions.

Next Steps

• Continued monitoring of 3i, LP's beneficial ownership as it may approach or exceed the 9.99% Blocker limit.
• Observation of any future conversions or exercises of warrants and convertible instruments.
• Tracking of Valion Bio, Inc.'s financial performance and operational progress, which will influence the value and exercise of these securities.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While 3i, LP's continued investment and the $1.5 million cash injection are positive, the significant portion of funds retained for past obligations and the potential for future dilution through convertible instruments and warrants create uncertainty. The 9.99% ownership blocker also limits immediate upside potential for the investor. The filing indicates ongoing financial restructuring rather than a clear growth catalyst.

Keywords

Valion Bio, Schedule 13D, 3i LP, Convertible Note, Preferred Stock, Warrants, Beneficial Ownership, Capital Raise